Between January 2001 and December 2002, LACHIS provided 134 courses of long-term home antimicrobial therapy for osteomyelitis. No cases of neutropenia were reported for the 121 courses of ...

Wockhardt receives CDSCO approval for Zaynich (Zidebactam/Cefepime) antibiotic for complicated urinary tract infections in ...

Learn everything you need to know about Cefepime-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Credit: Getty Images. A PDUFA target date of February 22, 2024 has been set for this application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

Carbapenem-resistant Enterobacterales species and multidrug-resistant Pseudomonas aeruginosa are global health threats. Cefepime–taniborbactam is an investigational β-lactam and β-lactamase inhibitor ...

June 26, 2012 – The US Food and Drug Administration (FDA) is reminding healthcare professionals about the need to adjust the dosage of the antibacterial drug cefepime in patients with renal impairment ...

The FDA approved the combination of cefepime and enmetazobactam (Exblifep) for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis, caused by designated ...

Topline Data from Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) expected first quarter 2022 BARDA extends cost-sharing contract to ...

Please provide your email address to receive an email when new articles are posted on . McGovern PC, et al. Abstract 731. Presented at: IDWeek; Oct. 19- 23, 2022. Washington (hybrid meeting). A ...

Details concerning the Cefepime combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and ...

Wockhardt on Monday has inched closer to commercialising its novel antibiotic Zaynich for treating hard‑to‑treat gram‑negative infections, after India’s drug regulator’s expert panel gave its nod.

Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...